Patient-reported outcome and survival in premenopausal hormone receptor-positive breast cancer patients at moderate to high risk: comparing toremifene with aromatase inhibitor in a real-world study
机构：[1]Sun Yat sen Univ, Sun Yat sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangdong Hong Kong Joint Lab RNA Med, Guangzhou, Guangdong, Peoples R China中山大学附属第二医院[2]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou, Guangdong, Peoples R China中山大学附属第二医院[3]Sichuan Univ, West China Hosp, Inst Breast Hlth Med, Canc Ctr,Breast Ctr, Chengdu, Sichuan, Peoples R China四川大学华西医院
Toremifene, a selective estrogen receptor modulator, is commonly used in China for premenopausal breast cancer patients. This real-world study aimed to compare patient-reported outcome (PRO) and survival between toremifene and aromatase inhibitor (AI) plus ovarian function suppression (OFS) in patients with moderate-/high-risk premenopausal hormone receptor (HR)-positive breast cancer. The primary endpoint was PROs, assessed using SF-36 and EQ-5D-5L questionnaires between January and March 2023. A total of 392 patients were included, with 171 receiving toremifene and 221 receiving AI. The toremifene group showed significantly higher scores in the role physical (p = 0.034) and mental health (p = 0.009) dimensions of SF-36 and lower anxiety/depression (AD) scores (p = 0.038) in EQ-5D-5L compared to AI group. The estimated 5- and 8-year disease-free survival (DFS) rates were similar in toremifene and AI groups: 96.5% versus 91.9%, and 87.4% versus 87.8% (p = 0.39), respectively. Adverse event rates were similar in two groups, except for a greater risk of endometrial thickening (p < 0.001) and a lower occurrence of morning stiffness (p < 0.001) in the toremifene compared to the AI group. Premenopausal HR-positive breast cancer patients receiving toremifene plus OFS had better role physical and mental health outcomes and lower AD dimensions than those receiving AI plus OFS. Both treatments had comparable DFS and favorable tolerability profiles.
基金：
National Natural Science Foundation of China; National Key R&D Program of China [2021YFC3001000, 2022YFC2505101]; Fundamental Research Funds for the Central Universities; Sun Yat-sen University [2022005]; Major and Characteristic Technology Projects in Guangzhou Area [2023-2025, 2023P-ZD14]; Beijing Xisike Clinical Oncology Research Foundation [Y-pierrefabre202102-0107]; [82371739]; [82072907]; [82003311]; [U1911204]; [51861125203]
第一作者机构：[1]Sun Yat sen Univ, Sun Yat sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangdong Hong Kong Joint Lab RNA Med, Guangzhou, Guangdong, Peoples R China[2]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou, Guangdong, Peoples R China
共同第一作者：
通讯作者：
通讯机构：[1]Sun Yat sen Univ, Sun Yat sen Mem Hosp, Guangdong Prov Key Lab Malignant Tumor Epigenet &, Guangdong Hong Kong Joint Lab RNA Med, Guangzhou, Guangdong, Peoples R China[2]Sun Yat Sen Univ, Sun Yat Sen Mem Hosp, Breast Tumor Ctr, Guangzhou, Guangdong, Peoples R China[*1]Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, Guangdong-Hong Kong Joint Laboratory for RNA Medicine, Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China
推荐引用方式(GB/T 7714)：
Yang Yaping,Gan Fengxia,Luo Ting,et al.Patient-reported outcome and survival in premenopausal hormone receptor-positive breast cancer patients at moderate to high risk: comparing toremifene with aromatase inhibitor in a real-world study[J].MEDCOMM.2024,5(10):doi:10.1002/mco2.698.
APA：
Yang, Yaping,Gan, Fengxia,Luo, Ting,Lin, Qun,Yang, Wenqian...&Gong, Chang.(2024).Patient-reported outcome and survival in premenopausal hormone receptor-positive breast cancer patients at moderate to high risk: comparing toremifene with aromatase inhibitor in a real-world study.MEDCOMM,5,(10)
MLA：
Yang, Yaping,et al."Patient-reported outcome and survival in premenopausal hormone receptor-positive breast cancer patients at moderate to high risk: comparing toremifene with aromatase inhibitor in a real-world study".MEDCOMM 5..10(2024)
